These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6733276)

  • 1. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients.
    Hogge DE; Dutcher JP; Aisner J; Schiffer CA
    Blood; 1984 Jul; 64(1):253-6. PubMed ID: 6733276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients.
    Hussein MA; Lee EJ; Fletcher R; Schiffer CA
    Blood; 1996 May; 87(9):3959-62. PubMed ID: 8611727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion.
    Hogge DE; Dutcher JP; Aisner J; Schiffer CA
    Am J Hematol; 1983 Jun; 14(4):363-9. PubMed ID: 6859034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized.
    Dutcher JP; Schiffer CA; Aisner J; Wiernik PH
    Blood; 1981 Nov; 58(5):1007-11. PubMed ID: 6794674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion.
    Lee EJ; Norris D; Schiffer CA
    Transfusion; 1987; 27(3):245-7. PubMed ID: 3590287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients.
    Lee EJ; Schiffer CA
    Blood; 1987 Dec; 70(6):1727-9. PubMed ID: 3479195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates.
    O'Connell BA; Schiffer CA
    Transfusion; 1990 May; 30(4):314-7. PubMed ID: 2349631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
    Daly PA; Schiffer CA; Aisner J; Wiernik PH
    JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia.
    Gmür J; von Felten A; Osterwalder B; Honegger H; Hörmann A; Sauter C; Deubelbeiss K; Berchtold W; Metaxas M; Scali G; Frick PG
    Blood; 1983 Aug; 62(2):473-9. PubMed ID: 6871470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange for platelet alloimmunization.
    Bensinger WI; Buckner CD; Clift RA; Slichter SJ; Thomas ED
    Transplantation; 1986 May; 41(5):602-5. PubMed ID: 3705158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
    Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
    Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of in vitro assays in selection of compatible platelet donors.
    Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
    Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Aster RH
    Blood; 1977 Sep; 50(3):407-12. PubMed ID: 884318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of poor platelet transfusion responses with leukocyte-poor HL-A-matched platelet concentrates.
    Herzig RH; Herzig GP; Bull MI; Decter JA; Lohrmann HP; Stout FG; Yankee RA; Graw RG
    Blood; 1975 Nov; 46(5):743-50. PubMed ID: 1174708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombocyte transfusion: increase in platelets in relation to clinical and immunologic prerequisites].
    Panzer S; Maier F; Höcker P; Mayr WR; Hinterberger W
    Infusionsther Klin Ernahr; 1987 Apr; 14 Suppl 2():10-4. PubMed ID: 3298059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
    Slichter SJ; Davis K; Enright H; Braine H; Gernsheimer T; Kao KJ; Kickler T; Lee E; McFarland J; McCullough J; Rodey G; Schiffer CA; Woodson R
    Blood; 2005 May; 105(10):4106-14. PubMed ID: 15692069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.
    Schiffer CA; O'Connell B; Lee EJ
    Blood; 1989 Aug; 74(3):1172-6. PubMed ID: 2752158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
    Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients.
    Schiffer CA; Hogge DE; Aisner J; Dutcher JP; Lee EJ; Papenberg D
    Blood; 1984 Oct; 64(4):937-40. PubMed ID: 6592011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.